33m
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback